A Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AK138D1 in Advanced Solid Tumors
Latest Information Update: 18 Dec 2025
At a glance
- Drugs AK 138D1 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Akeso Biopharma
Most Recent Events
- 18 Dec 2025 New trial record